2023-08-28 17:41:14 ET
More on Lyell Immunopharma
- Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data
- MaxCyte in licensing pact with Lyell Immunopharma for cell therapies
- FDA clears Lyell Immunopharma IND for esophageal cancer candidate
- Lyell Immunopharma gets FDA signoff for clinical trial for CAR-T candidate
- Lyell Immunopharma’s chair of the board returns after medical leave
- Seeking Alpha’s Quant Rating on Lyell Immunopharma
- Earnings data for Lyell Immunopharma
For further details see:
JP Morgan cuts Lyell to neutral, pending data for cell therapy platform